文献速递中枢神经肿瘤放疗放疗物理与技术

整合高通量筛选与大尺度等效线图分析加速发现对癌细胞更具选择性的放射增敏剂

Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-29

研究在384孔板格式下,用160种可能干扰细胞对放射应答的化合物,在人胶质母细胞瘤(U251-MG)、宫颈癌(ME-180)细胞系及正常成纤维细胞(CCD-19Lu)上筛选,结合大尺度计算剂量反应与等效线图分析鉴定协同放射增敏药物,并用96孔独立方案及集落形成实验验证。结果保留4种在U251-MG和ME-180两个细胞系两个等效应水平协同的化合物,以及11种仅在一个癌细胞系协同有效的化合物,其中5种对正常成纤维细胞毒性有限。

要点

  • 160种化合物在U251-MG、ME-180及CCD-19Lu细胞系中筛选,评估放射联合的协同与正常细胞毒性。
  • 4种化合物在U251-MG和ME-180两个细胞系两个等效应水平协同,11种仅在一个癌细胞系协同。
  • 15种候选放射增敏剂中5种对正常成纤维细胞毒性有限。

核心结论

  • 高通量放化疗筛选结合大尺度计算分析是鉴定协同药物-放射组合并同时评估对正常成纤维细胞非预期毒性的有效工具。
  • 该研究激起加速发现改善放射治疗治疗指数的高度所需药物的期望。

研究设计与样本

  • 在384孔板格式下,将160种可能干扰细胞对放射应答的化合物在U251-MG、ME-180及CCD-19Lu细胞系中筛选。
  • 药物暴露后照射或不照射,用高通量细胞显微镜评估短期细胞存活,并用计算大尺度剂量反应与等效线图方法分析。
  • 在ME-180细胞上用独立96孔方案及金标准集落形成实验确认先导化合物的协同作用。

主要发现

  • 保留4种在U251-MG和ME-180细胞系两个等效应水平协同的化合物,以及11种仅在一个癌细胞系协同有效的化合物。
  • 15种候选放射增敏剂中5种对正常成纤维细胞无论是否联合放射均显示有限毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-throughput screening (HTS) platforms have been widely used to identify candidate anticancer drugs and drug-drug combinations; however, HTS-based identification of new drug-ionizing radiation (IR) combinations has rarely been reported. Herein, we developed an integrated approach including cell-based HTS and computational large-scale isobolographic analysis to accelerate the identification of radiosensitizing compounds acting strongly and more specifically on cancer cells. METHODS AND MATERIALS: In a 384-well plate format, 160 compounds likely to interfere with the cell response to radiation were screened on human glioblastoma (U251-MG) and cervix carcinoma (ME-180) cell lines, as well as on normal fibroblasts (CCD-19Lu). After drug exposure, cells were irradiated or not and short-term cell survival was assessed by high-throughput cell microscopy. Computational large-scale dose-response and isobolographic approach were used to identify promising synergistic drugs radiosensitizing cancer cells rather than normal cells. Synergy of a promising compound was confirmed on ME-180 cells by an independent 96-well assay protocol, and finally, by the gold-standard colony forming assay. RESULTS: We retained 4 compounds synergistic at 2 isoeffects in U251-MG and ME-180 cell lines and 11 compounds synergistically effective in only one cancer cell line. Among these 15 promising radiosensitizers, 5 compounds showed limited toxicity combined or not with IR on normal fibroblasts. CONCLUSIONS: Overall, this study demonstrated that HTS chemoradiation screening together with large-scale computational analysis is an efficient tool to identify synergistic drug-IR combinations, with concomitant assessment of unwanted toxicity on normal fibroblasts. It sparks expectations to accelerate the discovery of highly desired agents improving the therapeutic index of radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Verrelle P, Gestraud P, Poyer F, et al. Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells. Int J Radiat Oncol Biol Phys. 2023. PMID: 37778425. doi:10.1016/j.ijrobp.2023.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。